Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced the first patient has been dosed in its Phase 2 WISPer ...

How do you conserve 80-year-old murals that have accumulated decades' worth of soot, salt and other deterioration?